Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $30.50 Consensus PT from Brokerages

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have received an average rating of “Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $30.50.

A number of equities analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, January 13th. UBS Group began coverage on shares of Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price objective on the stock. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and lifted their target price for the company from $22.00 to $31.00 in a research report on Friday, October 18th. Finally, Wedbush restated an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research report on Friday, October 25th.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Nina S. Kjellson sold 3,993 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total transaction of $65,325.48. Following the completion of the transaction, the director now owns 3,707,420 shares in the company, valued at $60,653,391.20. This trade represents a 0.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have sold 16,597 shares of company stock worth $270,500. Insiders own 15.40% of the company’s stock.

Hedge Funds Weigh In On Tyra Biosciences

Large investors have recently modified their holdings of the stock. Rhumbline Advisers boosted its stake in shares of Tyra Biosciences by 4.1% in the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company’s stock worth $364,000 after acquiring an additional 1,027 shares during the period. Charles Schwab Investment Management Inc. raised its position in Tyra Biosciences by 2.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 173,737 shares of the company’s stock valued at $4,085,000 after purchasing an additional 3,792 shares during the period. JPMorgan Chase & Co. raised its position in Tyra Biosciences by 1.1% during the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock valued at $8,667,000 after purchasing an additional 3,896 shares during the period. Ally Bridge Group NY LLC raised its holdings in shares of Tyra Biosciences by 2.0% in the third quarter. Ally Bridge Group NY LLC now owns 270,075 shares of the company’s stock worth $6,349,000 after buying an additional 5,415 shares during the period. Finally, Oppenheimer & Co. Inc. raised its holdings in shares of Tyra Biosciences by 9.0% in the third quarter. Oppenheimer & Co. Inc. now owns 76,806 shares of the company’s stock worth $1,806,000 after buying an additional 6,318 shares during the period. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Trading Down 4.2 %

Shares of NASDAQ TYRA opened at $13.85 on Friday. The stock has a fifty day moving average price of $15.26 and a 200 day moving average price of $18.93. The company has a market cap of $700.81 million, a P/E ratio of -8.60 and a beta of 1.05. Tyra Biosciences has a 12-month low of $13.27 and a 12-month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). On average, sell-side analysts forecast that Tyra Biosciences will post -1.57 EPS for the current fiscal year.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.